Search

Your search keyword '"Brunner, Hermine"' showing total 1,188 results

Search Constraints

Start Over You searched for: Author "Brunner, Hermine" Remove constraint Author: "Brunner, Hermine"
Sorry, I don't understand your search. ×
1,188 results on '"Brunner, Hermine"'

Search Results

102. Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis

103. 503 Developing a standardized steroid dosing regimen in pediatric proliferative lupus nephritis

104. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

105. 2021 DORIS definition of remission in SLE: final recommendations from an international task force

106. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab

107. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

112. Proceedings from the 4th NextGen Therapies for SJIA and MAS virtual symposium held February 13–14, 2022.

113. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.

116. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison

117. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis

121. A148: A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results

125. Efficacy and safety of tocilizumab for polyarticular-course juvenile idiopathic arthritis in the open-label two-year extension of a phase III trial

126. Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics.

131. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

132. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.

133. 2021 DORIS definition of remission in SLE:Final recommendations from an international task force

135. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data

136. Developing consensus treatment plans for proliferative lupus nephritis in childhood-onset systemic lupus erythematous

139. Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis

140. Achieving consensus on quality indicators (QI) for pediatric Systemic Lupus Erythematosus (pSLE)

141. Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)

145. Characterization Of Changes In Gene Expression and Inflammatory Proteins In Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy.: 1692

150. Contributors

Catalog

Books, media, physical & digital resources